Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms.

Vogt MR, Dowd KA, Engle M, Tesh RB, Johnson S, Pierson TC, Diamond MS.

J Virol. 2011 Nov;85(22):11567-80. doi: 10.1128/JVI.05859-11. Epub 2011 Sep 14.

2.

Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step.

Vogt MR, Moesker B, Goudsmit J, Jongeneelen M, Austin SK, Oliphant T, Nelson S, Pierson TC, Wilschut J, Throsby M, Diamond MS.

J Virol. 2009 Jul;83(13):6494-507. doi: 10.1128/JVI.00286-09. Epub 2009 Apr 22.

3.

A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus.

Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC.

PLoS Pathog. 2011 Jun;7(6):e1002111. doi: 10.1371/journal.ppat.1002111. Epub 2011 Jun 30.

4.

The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.

Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE Jr.

MBio. 2013 Nov 19;4(6):e00873-13. doi: 10.1128/mBio.00873-13.

5.

Induction of epitope-specific neutralizing antibodies against West Nile virus.

Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, Loeb M, Throsby M, Fremont DH, Pierson TC, Diamond MS.

J Virol. 2007 Nov;81(21):11828-39. Epub 2007 Aug 22.

6.

Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein.

Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A, Lachmi BE, Olshevsky U, Fremont DH, Pierson TC, Diamond MS.

J Virol. 2006 Dec;80(24):12149-59. Epub 2006 Oct 11.

7.

Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.

Fong RH, Banik SS, Mattia K, Barnes T, Tucker D, Liss N, Lu K, Selvarajah S, Srinivasan S, Mabila M, Miller A, Muench MO, Michault A, Rucker JB, Paes C, Simmons G, Kahle KM, Doranz BJ.

J Virol. 2014 Dec;88(24):14364-79. doi: 10.1128/JVI.01943-14. Epub 2014 Oct 1.

8.

Generation and analysis of novel plant-derived antibody-based therapeutic molecules against West Nile virus.

He J, Lai H, Engle M, Gorlatov S, Gruber C, Steinkellner H, Diamond MS, Chen Q.

PLoS One. 2014 Mar 27;9(3):e93541. doi: 10.1371/journal.pone.0093541. eCollection 2014.

10.

The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.

Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F.

Cell Host Microbe. 2010 Sep 16;8(3):271-83. doi: 10.1016/j.chom.2010.08.007.

11.

A recombinant novirhabdovirus presenting at the surface the E Glycoprotein from West Nile Virus (WNV) is immunogenic and provides partial protection against lethal WNV challenge in BALB/c mice.

Nzonza A, Lecollinet S, Chat S, Lowenski S, Mérour E, Biacchesi S, Brémont M.

PLoS One. 2014 Mar 24;9(3):e91766. doi: 10.1371/journal.pone.0091766. eCollection 2014.

12.

Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2.

da Silva Voorham JM, Rodenhuis-Zybert IA, Ayala Nuñez NV, Colpitts TM, van der Ende-Metselaar H, Fikrig E, Diamond MS, Wilschut J, Smit JM.

PLoS One. 2012;7(3):e29957. doi: 10.1371/journal.pone.0029957. Epub 2012 Mar 14.

13.

Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence.

McAuley AJ, Torres M, Plante JA, Huang CY, Bente DA, Beasley DW.

J Virol. 2016 Apr 14;90(9):4757-70. doi: 10.1128/JVI.02861-15. Print 2016 May.

14.

Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion-loop.

Chabierski S, Barzon L, Papa A, Niedrig M, Bramson JL, Richner JM, Palù G, Diamond MS, Ulbert S.

BMC Infect Dis. 2014 May 9;14:246. doi: 10.1186/1471-2334-14-246.

15.

Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.

Sukupolvi-Petty S, Brien JD, Austin SK, Shrestha B, Swayne S, Kahle K, Doranz BJ, Johnson S, Pierson TC, Fremont DH, Diamond MS.

J Virol. 2013 Aug;87(16):8826-42. doi: 10.1128/JVI.01314-13. Epub 2013 Jun 19.

16.

Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.

Dunn MD, Rossi SL, Carter DM, Vogt MR, Mehlhop E, Diamond MS, Ross TM.

Virol J. 2010 May 12;7:95. doi: 10.1186/1743-422X-7-95.

17.

A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.

Schneeweiss A, Chabierski S, Salomo M, Delaroque N, Al-Robaiy S, Grunwald T, Bürki K, Liebert UG, Ulbert S.

Vaccine. 2011 Aug 26;29(37):6352-7. doi: 10.1016/j.vaccine.2011.04.116. Epub 2011 May 17.

PMID:
21596075
18.

Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus.

Throsby M, Geuijen C, Goudsmit J, Bakker AQ, Korimbocus J, Kramer RA, Clijsters-van der Horst M, de Jong M, Jongeneelen M, Thijsse S, Smit R, Visser TJ, Bijl N, Marissen WE, Loeb M, Kelvin DJ, Preiser W, ter Meulen J, de Kruif J.

J Virol. 2006 Jul;80(14):6982-92.

19.

Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody.

Sultana H, Foellmer HG, Neelakanta G, Oliphant T, Engle M, Ledizet M, Krishnan MN, Bonafé N, Anthony KG, Marasco WA, Kaplan P, Montgomery RR, Diamond MS, Koski RA, Fikrig E.

J Immunol. 2009 Jul 1;183(1):650-60. doi: 10.4049/jimmunol.0900093. Epub 2009 Jun 17.

20.

Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus.

Mehlhop E, Nelson S, Jost CA, Gorlatov S, Johnson S, Fremont DH, Diamond MS, Pierson TC.

Cell Host Microbe. 2009 Oct 22;6(4):381-91. doi: 10.1016/j.chom.2009.09.003.

Supplemental Content

Support Center